Marijuana’s psychoactive compound may alter brain wiring in adolescents

In a mouse study designed to explore the impact of marijuana’s major psychoactive compound, THC, on teenage brains, Johns Hopkins Medicine researchers say they found changes to the structure of microglia, which are specialized brain immune cells, that may worsen a genetic predisposition to schizophrenia.

Kyverna says CAR-T manufacturing times can be cut through blood collection efficiencies

Clinical-stage biotech Kyverna Therapeutics revealed further details on how it can potentially shorten production timelines for autoimmune CAR-Ts by using its so-called “vein-to-vein” process. Kyverna,

January 26, 2024

Venous thromboembolism market projected to grow at 2.6% CAGR between 2022 and 2032 – Pharmaceutical Technology

Factor XI inhibitors are a key area for clinical trial development in VTE due to the associated decreased bleeding risk. Credit: Kateryna Kon via Shutterstock.

July 4, 2023

Pharmalittle: House panel inches into fixing drug shortages; pharma could face legal action over improper patent listings

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal

September 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.